Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.

Sun M, Meyer CP, Karam JA, de Velasco G, Chang SL, Pal SK, Trinh QD, Choueiri TK.

Eur J Surg Oncol. 2018 Jun 5. pii: S0748-7983(18)31103-X. doi: 10.1016/j.ejso.2018.05.026. [Epub ahead of print]

PMID:
29935840
2.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

PMID:
29748390
3.

Exosomes: Definition, Role in Tumor Development and Clinical Implications.

Carretero-González A, Otero I, Carril-Ajuria L, de Velasco G, Manso L.

Cancer Microenviron. 2018 Jun;11(1):13-21. doi: 10.1007/s12307-018-0211-7. Epub 2018 May 3. Review.

4.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

PMID:
29674707
5.

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.

Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G.

Oncotarget. 2018 Jan 20;9(9):8706-8715. doi: 10.18632/oncotarget.24283. eCollection 2018 Feb 2.

6.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
7.

The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.

Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR.

Clin Genitourin Cancer. 2018 Apr;16(2):e327-e333. doi: 10.1016/j.clgc.2017.11.005. Epub 2017 Dec 6.

PMID:
29361425
8.

The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.

Sun M, De Velasco G, Brastianos PK, Aizer AA, Martin A, Moreira R, Nguyen PL, Trinh QD, Choueiri TK.

Eur Urol Focus. 2018 Jan 5. pii: S2405-4569(17)30294-8. doi: 10.1016/j.euf.2017.12.007. [Epub ahead of print]

PMID:
29311016
9.

Urothelial cancer proteomics provides both prognostic and functional information.

de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D.

Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6.

10.

In Reply.

de Velasco G, Culhane AC, Heng DYC, Signoretti S, Choueiri TK.

Oncologist. 2017 Dec;22(12):1561. doi: 10.1634/theoncologist.2017-0283. Epub 2017 Sep 11. No abstract available.

11.

Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, Choueiri TK, González Del Alba A, Bellmunt J.

Clin Genitourin Cancer. 2017 Dec;15(6):e1089-e1094. doi: 10.1016/j.clgc.2017.07.012. Epub 2017 Aug 2.

PMID:
28864222
12.

Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.

de Velasco G, Gray KP, Hamieh L, Urun Y, Carol HA, Fay AP, Signoretti S, Kwiatkowski DJ, McDermott DF, Freedman M, Pomerantz MM, Choueiri TK.

Eur Urol Focus. 2016 Dec 15;2(6):633-639. doi: 10.1016/j.euf.2016.03.017. Epub 2016 Apr 23.

13.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ.

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

14.

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC.

Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048. Epub 2017 Apr 16.

15.

Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.

de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.

PMID:
28410911
16.

Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment.

Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, Choueiri TK.

Eur Urol. 2017 Aug;72(2):171-174. doi: 10.1016/j.eururo.2017.03.005. Epub 2017 Mar 27.

PMID:
28359734
17.

Biosimilar biologic drugs: a new frontier in medical care.

Geynisman DM, De Velasco G, Sewell KL, Jacobs I.

Postgrad Med. 2017 May;129(4):460-470. doi: 10.1080/00325481.2017.1311196. Epub 2017 Apr 3. Review.

PMID:
28343424
18.

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.

De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK.

Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2. doi: 10.1016/j.clgc.2017.01.005. Epub 2017 Jan 12.

PMID:
28254206
19.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2017 Mar 1;18(1):46. doi: 10.1186/s13059-017-1180-8. No abstract available.

20.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK.

Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28.

21.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

22.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

23.

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2016 Nov 17;17(1):231. Erratum in: Genome Biol. 2017 Mar 1;18(1):46.

24.

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK.

J Clin Oncol. 2016 Sep 6. pii: JCO667311. [Epub ahead of print]

25.

Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.

de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK.

Cancer Immunol Res. 2016 Oct;4(10):820-822. Epub 2016 Aug 18.

26.

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK.

J Natl Compr Canc Netw. 2016 Jul;14(7):820-4.

27.

Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, Choueiri TK.

J Clin Oncol. 2016 Sep 20;34(27):3267-75. doi: 10.1200/JCO.2016.66.7931. Epub 2016 Jun 20.

28.

A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.

McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK.

Cancer. 2016 Aug 1;122(15):2389-98. doi: 10.1002/cncr.30056. Epub 2016 May 19.

29.

Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.

Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ.

Cell Rep. 2016 Mar 15;14(10):2476-89. doi: 10.1016/j.celrep.2016.02.024. Epub 2016 Mar 3.

30.

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen E, Krajewski KM, Porta C, Pal S, Bellmunt J, McDermott DF, Heng DYC, Gray KP, Signoretti S.

Clin Cancer Res. 2016 May 15;22(10):2445-2452. doi: 10.1158/1078-0432.CCR-15-2631. Epub 2016 Feb 1.

31.

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

JAMA Oncol. 2016 Apr;2(4):500-7. doi: 10.1001/jamaoncol.2015.4917.

PMID:
26720632
32.

Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.

de Velasco G, Krajewski KM, Albiges L, Awad MM, Bellmunt J, Hodi FS, Choueiri TK.

Cancer Immunol Res. 2016 Jan;4(1):12-7. doi: 10.1158/2326-6066.CIR-15-0197. Epub 2015 Nov 20.

33.

Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK.

Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5.

34.

Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.

de Velasco G, Hamieh L, Mickey S, Choueiri TK.

Urol Oncol. 2015 Dec;33(12):538-45. doi: 10.1016/j.urolonc.2015.08.007. Epub 2015 Oct 9. Review.

35.

Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment.

de Velasco G, Bermas B, Choueiri TK.

Arthritis Rheumatol. 2016 Feb;68(2):556-7. doi: 10.1002/art.39406. No abstract available.

36.

Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.

Sepulveda-Sanchez J, Ramos A, Hilario A, DE Velasco G, Castellano D, Garcia DE LA Torre M, Rodon J, Lahn MF.

Oncol Lett. 2015 Jun;9(6):2442-2448. Epub 2015 Apr 8.

37.

Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature.

de Velasco G, Munoz C, Sepulveda JM, Castellano D.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E243-6. doi: 10.5489/cuaj.2264.

38.

Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction.

Sun M, de Velasco G, Trinh QD, Choueiri TK.

Eur Urol. 2016 Jan;69(1):92-3. doi: 10.1016/j.eururo.2015.05.040. Epub 2015 Jun 6. No abstract available.

PMID:
26056068
39.

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.

Castellano D, Puente J, de Velasco G, Chirivella I, López-Criado P, Mohedano N, Fernández O, García-Carbonero I, González MB, Grande E.

BMC Cancer. 2014 Oct 24;14:779. doi: 10.1186/1471-2407-14-779.

40.

Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.

Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vazquez F.

Cancer Treat Rev. 2013 May;39(3):230-40. doi: 10.1016/j.ctrv.2012.04.009. Epub 2012 May 28. Review.

PMID:
22647546
41.

Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.

Sánchez-Muñoz A, Mendiola C, Pérez-Ruiz E, Rodríguez-Sánchez CA, Jurado JM, Alonso-Carrión L, Ghanem I, de Velasco G, Quero-Blanco C, Alba E.

Oncology. 2010;79(1-2):98-104. doi: 10.1159/000320602. Epub 2010 Nov 15.

PMID:
21079407
42.

[Corsi's operation].

DE VELASCO G, HOLSCHNEIDER E.

Medicina (Mex). 1953 Jan 10;33(667):18-21. Undetermined Language. No abstract available.

PMID:
13054197

Supplemental Content

Loading ...
Support Center